Genflow Biosciences
CompanyUnited KingdomFounded 2021
Genflow Biosciences develops 4 assets, the furthest in veterinary (GF-1004). Mostly gene therapy and mrna acting on SIRT6, sirtuin signalling and DNA repair; based in the United Kingdom, founded in 2021.
- 4
- Assets
- Furthest stage
- Veterinary
- Raised
- £6.3m
- 0
- Trials
- 1
- Signal
Pipeline
4Plasmid DNA delivers the centenarian variant of SIRT6 for veterinary use in dogs.
Veterinary, Gene therapy, SIRT6
Lipid nanoparticles deliver mRNA expressing a centenarian variant of SIRT6.
Preclinical, mRNA, SIRT6, aging
An mRNA formulation delivers SIRT6c to dermal fibroblasts.
Preclinical, mRNA, SIRT6
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Funding rounds and grants8
- People9
- Signals3
- Similar companies6